Minh Mach, MD
Endocrinology · Burbank, CANPI 1831298736
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $502,049 of the $558,784 with a category attached, or 89.8%. Lilly USA, LLC accounts for 71.3% of it on its own, with 50 other manufacturers making up the rest. Reporting peaked in 2023 at $116,429 and has fallen 52.4% since, to $55,432 in 2025. Among endocrinology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,308 payments — averaging $242.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$399K
- Boehringer Ingelheim$53K
- AstraZeneca$40K
- Sanofi-aventis U.S. LLC$32K
- Mannkind Corporation$13K
- Medtronic$4K
- plus $19K from 45 others
Across 6 payments — averaging $15,157 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Royal Biologics, Inc.$86K
- Novo Nordisk AS$5K
What the payments were for
- Consulting fees$7,5251%
- Speaking & faculty fees$502,04990%
- Travel & lodging$12,6862%
- Food & beverage$36,3977%
- Education$690%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$177,841
- MOUNJARO$169,237
- TRULICITY$68,430
- FARXIGA$37,603
- BAQSIMI$19,588
- TOUJEO$15,837
- SOLIQUA 100/33$15,192
- V-GO$6,525
- Tirosint$2,625
- AFREZZA$2,550
- MINIMED 770G$1,536
- FREESTYLE LIBRE 3$1,000
How this compares
$558,784 in reported general payments places this provider in the 95th percentile of 58 endocrinology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 315 | $380,663 |
| MounjaroTirzepatide | 245 | $313,440 |
| JardianceEmpagliflozin | 357 | $284,087 |
| TrulicityDulaglutide | 219 | $277,917 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 183 | $158,696 |
| FarxigaDapagliflozin Propanediol | 165 | $132,422 |
| TradjentaLinagliptin | 179 | $127,778 |
| JanuviaSitagliptin Phosphate | 140 | $120,868 |
| JanumetSitagliptin Phos/Metformin Hcl | 104 | $111,963 |
| GlyxambiEmpagliflozin/Linagliptin | 106 | $99,345 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 96 | $97,175 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 119 | $89,393 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 41 | $73,577 |
| Xigduo XrDapaglifloz Propaned/Metformin | 82 | $68,241 |
| RybelsusSemaglutide | 43 | $62,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Glyxambi, Trijardy Xr | $52,579 | $759,300944 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $398,640 | $605,391510 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $2,808 | $484,526415 claims |
| MerckJanuvia, Janumet, Janumet Xr | $646 | $266,914290 claims |
| AstraZenecaFarxiga | $39,775 | $132,422165 claims |
| Radius Health, Inc.Tymlos | $668 | $28,57511 claims |
| Mannkind CorporationAfrezza | $12,592 | $26,60119 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $32,033 | $17,91921 claims |
| AbbVieSynthroid | $637 | $8,371196 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 58 endocrinology providers in California.
Other endocrinology in Burbank
- Shawna WeislerBurbank$45K
- Joseph HawkinsFresno$477K
- Michael BushBeverly Hills$380K
- Ashiq PatelLancaster$32K
- Paul AzerBeverly Hills$25K
- Michael TranAnaheim$16K
- Samuel MayedaOrange$11K
- Daniel KaplanSan Leandro$8K
- Amy van BuiMission Viejo$8K
- Sandeep ChaudharyLaguna Hills$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.